Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

ORIC Pharmaceuticals, Inc. ORIC NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
59/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$21.75
+106.6%

ORIC Pharmaceuticals, Inc. (ORIC) is a Biotechnology company in the Healthcare sector, currently trading at $10.53. It has a SharesGrow Score of 57/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is ORIC = $22 (+106.6% upside).

Valuation: ORIC trades at a trailing Price-to-Earnings (P/E) of -6.4 (S&P 500 average ~25).

Net income is $129M (loss), growing at -12.8%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $12M against $384M equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 14.13 (strong liquidity). Debt-to-assets is 2.8%. Total assets: $411M.

Analyst outlook: 10 / 10 analysts rate ORIC as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 40/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

$21.75
▲ 106.55% Upside
Average Price Target
Based on 10 Wall Street analysts offering 12-month price targets for ORIC Pharmaceuticals, Inc., the average price target is $21.75, with a high forecast of $25.00, and a low forecast of $15.00.
Highest Price Target
$25.00
Average Price Target
$21.75
Lowest Price Target
$15.00

ORIC SharesGrow Score Overview

71/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ORIC

✓
VALUE Pass
100/100
ORIC trades at a trailing Price-to-Earnings (P/E) of -6.4 (S&P 500 average ~25). Forward PEG -0.72 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $22, implying +108.9% from the current price $11. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
ORIC: +0%/yr revenue is, -12.8%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet ORIC: Debt-to-Equity (D/E) ratio 0.03 (conservative), Current ratio is 14.13 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
ORIC: Gross margin is 0% (+0 pp trend), $1B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 10 / 10 analysts rate ORIC as buy (100%). Analyst consensus target is $22 (+108.9% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range3.895-14.93
Volume948.67K
Avg Volume (30D)1.97M
Market Cap$1.06B
Beta (1Y)1.36
Share Statistics
EPS (TTM)-1.47
Shares Outstanding$87.79M
IPO Date2020-04-24
Employees122
CEOJacob Chacko
Financial Highlights & Ratios
Gross Profit$-1.22M
EBITDA$-128.25M
Net Income$-129.47M
Operating Income$-143M
Total Cash$281.49M
Total Debt$11.55M
Net Debt$-34.12M
Total Assets$411M
Price / Earnings (P/E)-7.2
Analyst Forecast
1Y Price Target$23.50
Target High$25.00
Target Low$15.00
Upside+123.2%
Rating ConsensusBuy
Analysts Covering10
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS68622P1093

Price Chart

Track all markets on TradingView
ORIC
ORIC Pharmaceuticals, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
3.90 52WK RANGE 14.93

People Also View

CELC
CELC
Celcuity Inc.
$120.85
+0.37%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.16
-2.01%
 ELVN
ELVN
Enliven Therapeutics, Inc.
$44.85
+2.33%
 PHVS
PHVS
Pharvaris N.V.
$28.68
+2.87%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$27.32
+0.59%
 CGEM
CGEM
Cullinan Oncology, Inc.
$14.35
+0.70%
 CCCC
CCCC
C4 Therapeutics, Inc.
$2.76
+0.91%
 IMRX
IMRX
Immuneering Corporation
$5.41
-5.09%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message